Noncovalent molecular interactions between antineoplastic drug gemcitabine and a carrier protein identified through spectroscopic and in silico methods

Int J Biol Macromol. 2021 Jul 1:182:993-1002. doi: 10.1016/j.ijbiomac.2021.04.049. Epub 2021 Apr 20.

Abstract

Herein we have studied the noncovalent molecular interactions between hen egg white lysozyme (HEWL) and the commonly employed antineoplastic drug gemcitabine through the cumulative implementation of spectroscopic techniques and in silico approaches. The formation of a complex between HEWL and gemcitabine was made evident by the differences between the UV-visible spectra of the protein and protein-gemcitabine complex. Fluorescence quenching of HEWL by gemcitabine was hardly detectable at room temperature, but it became prominent at higher temperatures. Very low values for the bimolecular quenching constant and the non-reciprocal dependence of quenching on temperature indicated that dynamic quenching was taking place. Analysis of experimental data indicated that the interaction was dominated by hydrophobic forces, while the results of a computational investigation suggested the concomitant contribution of hydrogen bonding. Gemcitabine binding induced modifications of the secondary structure of HEWL by slightly increasing the α-helical content of the protein. Finally, gemcitabine binding site was inferred to be located in HEWL big hydrophobic cavity.

Keywords: Dynamic quenching; Gemcitabine; Lysozyme; Molecular docking; Molecular dynamics.

MeSH terms

  • Antineoplastic Agents / chemistry*
  • Antineoplastic Agents / pharmacology
  • Binding Sites
  • Deoxycytidine / analogs & derivatives*
  • Deoxycytidine / chemistry
  • Deoxycytidine / pharmacology
  • Gemcitabine
  • Molecular Docking Simulation*
  • Muramidase / chemistry*
  • Muramidase / metabolism
  • Protein Binding

Substances

  • Antineoplastic Agents
  • Deoxycytidine
  • hen egg lysozyme
  • Muramidase
  • Gemcitabine